Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
RhuFab V2 safety and benefits maintained with continued dosing
Ft. Lauderdale-New results from the ongoing, Phase Ib/II open-label,randomized controlled trial of rhuFab V2 for the treatment of exudativeAMD show that a second course of treatment with up to four injection iswell-tolerated and provides ongoing biologic activity, reported JeffreyS. Heier, MD.
Related Videos
Related Content
